MediWound Set to Announce Q1 2025 Results with Insights

Author: Dylan Bailey Updated: 05-05-2025 08:26 AM

MediWound Preparing to Unveil First Quarter Financial Results

YAVNE, Israel – MediWound Ltd. (Nasdaq: MDWD), a leader in innovative enzymatic therapeutics aimed at tissue repair, is set to announce its financial results for the first quarter ending on March 31, 2025. The announcement will be made on a date in May that is integral to the company's timeline for engaging with stakeholders.

Management's Insights through Conference Call

The management team of MediWound will host a conference call and a live webcast at 8:30 a.m. Eastern Time to delve into the financial results and share meaningful corporate updates post-announcement. This platform will allow investors and interested parties to gain a clearer understanding of the company's recent progress and future strategies.

Details of the Conference Call

Participants looking to partake in this important discussion should dial in at least five minutes prior to the call. The specific dial-in numbers are:

Toll-Free: 1-844-676-8833
Israel: 1-80-921-2373
International: 1-412-634-6869

A live archive of the webcast will be accessible for replay, allowing those unable to attend the live discussion an opportunity to catch up on the information shared.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is driving innovation within the biotechnology sector, focusing on the development and commercialization of enzymatic therapies that address the need for non-invasive tissue repair solutions. Its flagship product, NexoBrid, has received FDA approval for the enzymatic removal of eschar in thermal burns, making it a critical treatment option within the U.S., European Union, Japan, and various global markets.

Advancements in Enzymatic Therapies

In addition to NexoBrid, MediWound is making significant strides with EscharEx, an investigational therapy currently in late-stage development aimed at effectively debriding chronic wounds. This product is poised to create a notable impact in the market due to its demonstrated clinical advantages over existing enzymatic products, ultimately targeting a vast market opportunity.

Company Contacts for Inquiries

MediWound encourages interested parties to reach out for more information. Contact details are as follows:

Hani Luxenburg
Chief Financial Officer
MediWound Ltd.
Email: ir@mediwound.com

Daniel Ferry
Managing Director
LifeSci Advisors, LLC
Email: daniel@lifesciadvisors.com

Media Contact:
Ellie Hanson
FINN Partners for MediWound
Email: ellie.hanson@finnpartners.com
Phone: +1-929-588-2008

Frequently Asked Questions

When does MediWound plan to report their financial results?

MediWound is expected to report its financial results for the first quarter on a specified date in May.

How can I participate in the earnings call?

You can join the conference call by dialing in at least five minutes before the scheduled start time using the provided dial-in numbers.

What innovative therapies is MediWound developing?

MediWound is developing enzymatic therapies, including NexoBrid and EscharEx, aimed at enhancing tissue repair without surgical intervention.

Where can I access the archived webcast of the call?

An archived version of the webcast will be available on the Investors section of the MediWound website.

Who should I contact for more information about MediWound?

For more inquiries, you can reach out to Hani Luxenburg or Daniel Ferry using the email addresses provided above.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.